[HTML][HTML] Poly (ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
A Tattersall, N Ryan, AJ Wiggans… - The Cochrane …, 2022 - ncbi.nlm.nih.gov
Background Ovarian cancer is the sixth most common cancer in women world‐wide.
Epithelial ovarian cancer (EOC) is the most common; three‐quarters of women present …
Epithelial ovarian cancer (EOC) is the most common; three‐quarters of women present …
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
A Tattersall, N Ryan, AJ Wiggans… - The Cochrane …, 2022 - europepmc.org
Background Ovarian cancer is the sixth most common cancer in women world-wide.
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …
[引用][C] Poly (ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
Cochrane Gynaecological, Neuro … - Cochrane Database …, 1996 - cochranelibrary.com
Background Ovarian cancer is the sixth most common cancer in women world‐wide.
Epithelial ovarian cancer (EOC) is the most common; three‐quarters of women present …
Epithelial ovarian cancer (EOC) is the most common; three‐quarters of women present …
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
A Tattersall, N Ryan, AJ Wiggans… - The Cochrane …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Ovarian cancer is the sixth most common cancer in women world-wide.
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …
[PDF][PDF] Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
A Tattersall, N Ryan, AJ Wiggans, E Rogozińska… - 2022 - researchgate.net
Background Ovarian cancer is the sixth most common cancer in women world-wide.
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
A Tattersall, N Ryan, AJ Wiggans… - Cochrane Database …, 2022 - discovery.ucl.ac.uk
BACKGROUND: Ovarian cancer is the sixth most common cancer in women world-wide.
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
A Tattersall, N Ryan, AJ Wiggans… - The Cochrane …, 2022 - europepmc.org
Background Ovarian cancer is the sixth most common cancer in women world-wide.
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …
Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when …